+

WO2004093919A3 - Cible pour la therapie du cancer et la decouverte de medicaments - Google Patents

Cible pour la therapie du cancer et la decouverte de medicaments Download PDF

Info

Publication number
WO2004093919A3
WO2004093919A3 PCT/GB2004/001743 GB2004001743W WO2004093919A3 WO 2004093919 A3 WO2004093919 A3 WO 2004093919A3 GB 2004001743 W GB2004001743 W GB 2004001743W WO 2004093919 A3 WO2004093919 A3 WO 2004093919A3
Authority
WO
WIPO (PCT)
Prior art keywords
target
cancer therapy
drug discovery
cancer
discovery
Prior art date
Application number
PCT/GB2004/001743
Other languages
English (en)
Other versions
WO2004093919A2 (fr
Inventor
Heike Laman
Original Assignee
Univ London
Heike Laman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London, Heike Laman filed Critical Univ London
Publication of WO2004093919A2 publication Critical patent/WO2004093919A2/fr
Publication of WO2004093919A3 publication Critical patent/WO2004093919A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un inhibiteur de Fbx7 lors de la production d'un médicament destiné à être utilisé pour le traitement d'un cancer.
PCT/GB2004/001743 2003-04-22 2004-04-22 Cible pour la therapie du cancer et la decouverte de medicaments WO2004093919A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0309116A GB0309116D0 (en) 2003-04-22 2003-04-22 Target for cancer therapy and drug discovery
GB0309116.2 2003-04-22

Publications (2)

Publication Number Publication Date
WO2004093919A2 WO2004093919A2 (fr) 2004-11-04
WO2004093919A3 true WO2004093919A3 (fr) 2004-12-09

Family

ID=9957090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/001743 WO2004093919A2 (fr) 2003-04-22 2004-04-22 Cible pour la therapie du cancer et la decouverte de medicaments

Country Status (2)

Country Link
GB (1) GB0309116D0 (fr)
WO (1) WO2004093919A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012679A1 (fr) * 1998-08-28 2000-03-09 New York University Nouvelles ubiquitine ligases utiles comme cibles therapeutiques
WO2000077207A2 (fr) * 1999-06-11 2000-12-21 The Burnham Institute Acides nucleiques codant pour les proteines participant a la decomposition de proteines et produits et procedes qui y sont lies
WO2002055665A2 (fr) * 2001-01-05 2002-07-18 Univ New York Procedes destines a identifier des composes utiles dans le traitement de troubles de proliferation et de differenciation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012679A1 (fr) * 1998-08-28 2000-03-09 New York University Nouvelles ubiquitine ligases utiles comme cibles therapeutiques
WO2000077207A2 (fr) * 1999-06-11 2000-12-21 The Burnham Institute Acides nucleiques codant pour les proteines participant a la decomposition de proteines et produits et procedes qui y sont lies
WO2002055665A2 (fr) * 2001-01-05 2002-07-18 Univ New York Procedes destines a identifier des composes utiles dans le traitement de troubles de proliferation et de differenciation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CENCIARELLI C ET AL: "IDENTIFICATION OF A FAMILY OF HUMAN F-BOX PROTEINS", CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 9, 1999, pages 1177 - 1179, XP000953487, ISSN: 0960-9822 *
CENCIARELLI C. ET AL.: "Supplementary material: Identification of a family of human F-box proteins", CURRENT BIOLOGY, vol. 9, 11 October 1999 (1999-10-11), pages S1 - S3, XP002295598 *
GANIATSAS SOULA ET AL: "A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT", ONCOGENE, vol. 20, no. 28, 21 June 2001 (2001-06-21), pages 3641 - 3650, XP002295597, ISSN: 0950-9232 *
KIPREOS E T ET AL: "The F-box protein family.", GENOME BIOLOGY 2000, vol. 1, no. 5, 2000, pages 3002.1 - 3002.7, XP002295599, ISSN: 1465-6914 *
PAGANO MICHELE ET AL: "When protein destruction runs amok, malignancy is on the loose.", CANCER CELL. OCT 2003, vol. 4, no. 4, October 2003 (2003-10-01), pages 251 - 256, XP002295600, ISSN: 1535-6108 *
RUBINSON D A ET AL: "A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 33, March 2003 (2003-03-01), pages 401 - 406, XP002973404, ISSN: 1061-4036 *
RUSSELL ADRIAN ET AL: "Inhibitory effect of p21 in MCF-7 cells is overcome by its coordinated stabilization with D-type cyclins", ONCOGENE, vol. 18, no. 47, 11 November 1999 (1999-11-11), pages 6454 - 6459, XP002295596, ISSN: 0950-9232 *
SHEN C ET AL: "Gene silencing by adenovirus-delivered siRNA", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 539, no. 1-3, 27 March 2003 (2003-03-27), pages 111 - 114, XP004415445, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
WO2004093919A2 (fr) 2004-11-04
GB0309116D0 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
WO2004064728A3 (fr) Composes de tetracycline possedant des activites therapeutiques ciblees
AU2003220317A1 (en) Methods and drug delivery systems for the treatment of orofacial diseases
WO2003042246A3 (fr) Traitement medical
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
IL164599A0 (en) Combination therapy for the treatment of cancer
AU2003297621A1 (en) Medical devices for delivery of therapeutic agents
WO2003096979A3 (fr) Pharmacotherapie destinee a une maladie coeliaque
AU2003300791A1 (en) Combination therapy for the treatment of pain
AUPS054702A0 (en) Cancer therapy
AU2003219555A1 (en) Depsipeptide for therapy of kidney cancer
AU2002347747A1 (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
AU2003222449A1 (en) Medicine for treating cancer
AU2001263383A1 (en) Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
WO2005007149A8 (fr) Ambroxol pour le traitement de douleurs aigues
AU2003245927A1 (en) Target genes for the diagnosis and treatment of cancer
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2003269133A1 (en) Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug
AU2003251513A1 (en) Rsk inhibitors and therapeutic uses thereof
IL172704A (en) Pharmaceuticals containing salinosporamide compound and use of this compound for the preparation of a cancer drug
WO2007077454A3 (fr) Composition therapeutique
WO2004093919A3 (fr) Cible pour la therapie du cancer et la decouverte de medicaments
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003296545A1 (en) Use of a trpm8-activating substance for the treatment of tumours
AU2003239144A1 (en) Combination of ablation and controlled drug delivery for the tre atment of cancer
AU2002339102A1 (en) Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载